Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
The National New Materials Industry Upgrading Fund is a Chinese state-backed investment vehicle focused on accelerating the development and commercialization of advanced materials. While its mandate is broad, it maintains a significant focus on the life sciences sector, investing in high-performance medical materials, biocompatible polymers, and advanced pharmaceutical packaging. The fund aims to reduce dependency on imported high-end materials by supporting domestic innovation in biotechnology and medical device manufacturing. It operates as a strategic investor, providing capital to growth-stage companies that are critical to the healthcare supply chain.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Upgrading New Materials Fund.